Portage Biotech Unveils Promising Preclinical Data for PORT-7 in Mesothelioma, Paving Way for First-In-Human Trial

April 28, 2025

DENVER, Colo., Apr 28, 2025 (247marketnews.com)- Portage Biotech (NASDAQ:PRTG) released compelling preclinical efficacy data for PORT-7 (TT-4), a selective adenosine A2B receptor inhibitor, supporting its advancement toward a first-in-human clinical trial. The data, to be presented by Dr. Luciano Mutti of the University of L’Aquila, Italy, a globally recognized mesothelioma expert, at today’s American Association for Cancer Research (AACR) Annual Meeting in Chicago, highlight PORT-7’s potential as a novel therapy for mesothelioma, an aggressive cancer with limited treatment options.

PORT-7: Breakthrough Preclinical Results

In a murine mesothelioma model, PORT-7 demonstrated superior single-agent activity compared to anti-PD1 antibody treatment. The combination of PORT-7 and anti-PD1 outperformed either therapy alone, showing enhanced tumor suppression. Immunohistochemistry revealed tertiary lymphoid structures in tumors treated with the combination, indicating a robust immune response, alongside increased immune effector cells. These findings suggest PORT-7 could overcome immune resistance in mesothelioma, a disease with a five-year survival rate of ~10% and ~3,000 annual U.S. diagnoses, per the American Cancer Society.

Synergistic Strategy: Combining PORT-6 and PORT-7

Portage is also advancing PORT-6, a potent A2A adenosine receptor inhibitor, in the dose-escalation phase of its ADPORT-601 trial. The company plans to co-administer PORT-6 and PORT-7, marking the first clinical combination of highly selective A2A and A2B antagonists. This innovative approach aims to fully neutralize adenosine-mediated immune suppression in the tumor microenvironment, enhancing anti-tumor responses across solid tumors. By targeting both adenosine pathways, Portage seeks to broaden immunotherapy’s impact, addressing a critical unmet need in oncology.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (PRTG)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.